Differentiating Treatment-Induced Necrosis From Recurrent/Progressive Brain Tumor Using Nonmodel-Based Semiquantitative Indices Derived From Dynamic Contrast-Enhanced T1-Weighted Mr Perfusion

摘要

Differentiating treatment-induced necrosis (TIN) from recurrent/progressive tumor (RPT) in brain tumor patients using conventional morphologic imaging features is a very challenging task. Functional imaging techniques also offer moderate success due to the complexity of the tissue microenvironment and the inherent limitation of the various modalities and techniques. The purpose of this retrospective study was to assess the utility of nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion (DCET1MRP) in differentiating TIN from RPT. Twenty-nine patients with previously treated brain tumors who showed recurrent or progressive enhancing lesion on follow-up MRI underwent DCET1MRP. Another 8 patients with treatment-naive high-grade gliomas who also underwent DCET1MRP were included as the control group. Semiquantitative indices derived from DCET1MRP included maximum slope of enhancement in initial vascular phase (MSIVP), normalized MSIVP (nMSIVP), normalized slope of delayed equilibrium phase (nSDEP), and initial area under the time-intensity curve (IAUC) at 60 and 120 s (IAUC_60 and IAUC_120) obtained from the enhancement curve. There was a statistically significant difference between the 2 groups (P<.01), with theRPT group showing higher MSIVP (15.78 vs 8.06), nMSIVP (0.046 vs 0.028), nIAUC60 (33.07 vs 6.44), and nIAUC_120 (80.14 vs 65.55) compared with the TIN group. nSDEP was significantly lower in the RPT group (7.20 x 10~(-5) vs 15.35 x 10~(-5) compared with the TIN group. Analysis of the receiver-operating-characteristic curve showed nMSIVP to be the best single predictor of RPT, with very high (95 %) sensitivity and high (78%) specificity. Thus, nonmodel-based semi-quantitative indices derived from DCET1MRP that are relatively easy to derive and do not require a complex model-based approach may aid in differentiating RPT from TIN and can be used as robust noninvasive imaging biomarkers.